Alligator Bioscience AB, of Lund, Sweden, has contracted with Södertälje, Sweden-based Cobra Biologics, asking it to develop a second cell line for production of Alligator's new drug candidate ADC-1015, a bispecific immune activator. Terms were not disclosed.